Clinical trial
A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer
NCT01917279 is registered in ClinicalTrials.gov with Binghe Xu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer
- Lead sponsor
- Binghe Xu
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- October 31, 2013
- Completion date
- July 31, 2021
- Enrollment
- 280 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.